Trial result page for

[Idiopathic Pulmonary Fibrosis (IPF)]

A clinical study to test how effective and safe GLPG1690 is for subjects with Idiopathic Pulmonary Fibrosis (IPF) when used together with standard of care (ISABELA1)

Recruiting

← Back to search results

Download this page Email this page

In this trial, doctors hope to find out how the study drug works together with your current standard treatment in terms of its effects on your lung function and IPF in general. People with IPF have increased levels of something called autotaxin, which is thought to have a role in the progression of IPF. The trial is investigating whether decreasing the activity of autotaxin can have a positive effect. It will also look at how well the study drug is tolerated.

Trial purpose

This study is comparing <different doses of> {GLPGXXX} <with a> <placebo> <comparator (an already approved drug)> to see whether {GLPGXXX} helps to treat {enter disease indication} and is safe to use. About {xx} participants will take part. About **750 participants** will take part.

Gender	Age range	Phase	Study dates
Male and female	40 years and older	Phase 3	Nov 2018 - Dec 2020

Eligibility criteria

Inclusion criteria +

Exclusion criteria +

Where to participate



COUNTRY	LOCATION	TRIAL STATUS
United States	Rhode Island Hospital, Providence, Rhode Island, United States, 02903	Not yet recruiting

Belgium	CHU UCL Namur asbl - Site Godinne, Yvoir, Belgium, 5530	Recruiting
Brazil	Irmandade Da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil, 90035-074	Recruiting
United Kingdom	Birmingham Heartlands Hospital, Birmingham, United Kingdom, B9 5SS	Recruiting
Australia	Royal Adelaide Hospital, Adelaide, Australia, 5000	Completed

WHAT TO DO NEXT IF YOU'RE INTERESTED IN THIS TRIAL

Protocol number:	Clinicaltrials.gov identifier:	EudraCT Number:	Product/drug type:
GLPG1690-CL-303	NCT03711162	2018-001405-87	GLPG1690

Official title: A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis

← Back to search results

Download this page Email this page